The Human Gene Editing Debate

· Highbridge Audio · Lukija: Victor Bevine
Äänikirja
5 h 17 min
Lyhentämätön
Kelvollinen
Arvioita ja arvosteluja ei ole vahvistettu Lue lisää
Haluatko näytteen, jonka kesto on 31 min? Kuuntele milloin tahansa, jopa offline-tilassa. 
Lisää

Tietoa tästä äänikirjasta

In 2018 the first genetically modified babies were reportedly born in China, made possible by the invention of CRISPR technology in 2012. This controversial advancement overturned the pre-existing moral consensus, which had held for over fifty years before: while gene editing an adult person was morally acceptable, modifying babies, and thus subsequent generations, crossed a significant moral line. If this line is passed over, scientists will be left without an agreed-upon ethical limit. What do we do now?



John H. Evans here provides a meta-level guide to how these debates move forward and their significance to society. He explains how the bioethical debate has long been characterized as a slippery slope, with consensually ethical use at the top, nightmarish dystopia at the bottom, and specific agreed-upon limits in between, which draw the lines between the ethical and the unethical. Evans frames his analysis around these limits, or barriers. He examines the history of how barriers were placed, then fell, then replaced by new ones, and discusses how these insights inform where the debate may head. He evaluates other proposed barriers relevant to where we are now, projects that most of the barriers suggested by scientists and bioethicists will not hold, and cautiously identifies a few that could serve as the moral boundary for the next generation.

Arvioi tämä äänikirja

Kerro meille mielipiteesi.

Kuuntelutiedot

Älypuhelimet ja tabletit
Asenna Google Play Kirjat ‑sovellus Androidille tai iPadille/iPhonelle. Se synkronoituu automaattisesti tilisi kanssa, jolloin voit lukea online- tai offline-tilassa missä tahansa oletkin.
Kannettavat ja pöytätietokoneet
Voit lukea Google Playsta ostamiasi kirjoja tietokoneesi verkkoselaimella.